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ABSTRACT 
  
Background: Approximately one-third of HIV-infected children experience virological failure 
within two years of initiating antiretroviral therapy (ART).  We determined the probability of 
switch to second-line ART or viral load (VL) re-suppression without switch among children 
who experienced VL rebound on first-line ART in an observational cohort in the UK/Ireland. 
Methods: Children with VL rebound (confirmed VL>400c/ml following suppression <400c/ml) 
on first-line ART were included. Competing risk analysis estimated the probability of: switch 
to second-line; confirmed re-suppression (two consecutive VL<400c/ml) without switch; and 
continued VL>400c/ml without switch. Predictors of time to switch were assessed.    
Findings: Of 900 children starting first-line ART who had VL<400c/ml by one year, 170 
(19%) experienced VL rebound by median [IQR] 20·6 months [9·7-40·5]. At rebound, 
median age was 10·6 years [5·6-13·4], VL 3·6 log10c/ml [3·1-4·2], and CD4% 24 [17-32]. 
Eighty-nine (52%) switched to second-line ART at median 4·9 months [1·7-13·4] after VL 
rebound, 53 (31%) re-suppressed without switch (61% of those on PI-based and 24% of 
those on NNRTI-based first-line regimens), while 28 (16%) neither re-suppressed nor 
switched. At 12 months after rebound, probabilities of switch or re-suppression without 
switch were 38% (95% CI 30-45) and 27% (95% CI 21-34), respectively. Faster time to 
switch was associated with higher VL (p<0·0001), later calendar year (p=0·02) at VL 
rebound, and NNRTI- or triple NRTI- versus PI-based first-line (p=0·001).   
Interpretation: One-third of children with VL rebound re-suppressed without switch. The 
possibility of re-suppression with adherence support should be considered prior to switching. 
Funding: NHS England  
 
Word count: 247 
  
4 
PANEL 
 
Systematic review 
We searched PubMed using the terms “HIV”, “antiretroviral therapy”, “switch”, “second line” 
and “children”. We identified 17 publications with data on children from a variety of settings 
which analysed either long-term virological patient outcomes1,3,4,13,25, durability of first-line 
ART 2,9,18,19,22 or response to second-line ART8,23,24,26-29.  Only two studies have reported 
outcomes following viral load rebound and the probability of switch or resuppression without 
switch in routine care19,22.   
 
Interpretation 
Our study adds to the evidence about patient outcomes following viral load rebound on first-
line antiretroviral therapy. Our well-established cohort contains ~900 HIV-infected children 
initiated on combination therapy, with median follow up of 5·4 years after start of ART. We 
analysed the patient outcomes of the 19% of children with confirmed viral rebound, of whom 
half switched to second-line ART. However, a further third re-suppressed without switch to 
second line treatment, including 25% of children on NNRTI- and 61% on PI-based first line 
regimens.  Children with lower CD4%, higher viral load, on NNRTI-based regimens at time of 
virological rebound, and those rebounding in later calendar years were more likely to switch. 
The possibility of re-suppression, which is comparable to that seen in adults20, should be 
considered prior to treatment switch; adherence counselling, dosing review and resistance 
testing can be used to inform patient management. 
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INTRODUCTION 
 
The aim of combination antiretroviral therapy (ART) in HIV-infected children is to achieve 
sustained viral suppression, immune reconstitution and to prevent disease progression.  
Several papers report that within two years of first-line ART initiation, 33-38% of children 
experience virological failure; this varies with age and type of first-line ART1-4. This has 
raised concerns regarding the sustainability and long-term treatment options for children, 
who are recommended immediate ART from infancy and will require lifelong treatment but 
are faced with a limited range of antiretrovirals available in paediatric formulations5, 6. Current 
guidelines recommend adherence support following raised viral load (VL) and switch to 
second-line ART if confirmed VL rebound within 6 months, particularly for children on non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens due to the low genetic 
barrier to resistance and risk of rapid accumulation of resistance in these patients5-7. 
However, the threshold for defining VL failure and optimal timing of switch to second-line 
ART are less clear. To date, only one trial has compared thresholds for switch in children, 
the PENPACT-1 trial where children who switched at VL rebound at ≥1,000c/ml versus 
≥30,000c/ml (over median time 60 months) showed no difference in VL suppression at four 
years by this randomisation, nor by the concurrent randomisation to protease inhibitor (PI) or 
NNRTI-based regimens. Delayed switching on NNRTI-based ART increased nucleoside 
reverse transcriptase inhibitor (NRTI) but not NNRTI resistance (with the latter occurring 
rapidly after VL rebound ≥1,000c/ml). PENPACT-1 highlighted the more forgiving nature of 
boosted PIs compared to NNRTIs; the authors concluded that delayed switching on PI-
based ART may be reasonable where future drug options are limited as the risk of 
development of PI resistance or NRTI thymidine analogue mutations (TAMS) was minimal, 
which has been observed in other studies8-12. Treatment guidelines stress the need for 
adherence counselling, attention to medication intolerance and pharmacokinetic/dosing 
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issues, as well as confirmation of VL rebound before switching, in order to maximise 
durability of first-line and response to second-line ART6.  
 
However, there are scarce data on the ‘real-life’ management and outcomes following 
virological failure on first-line ART, which would help inform both the timing and threshold for 
switching following VL rebound in HIV-infected children. We therefore assessed the 
probability of switch to second-line therapy or resuppression without switch among children 
who experienced confirmed VL rebound >400c/ml on first-line therapy within the 
Collaborative HIV Paediatric Study (CHIPS) in UK and Ireland. 
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METHODS 
 
CHIPS is a multi-centre cohort study of all HIV-infected children receiving paediatric HIV 
care in the UK and Ireland, as described elsewhere13.  In brief, all children presenting in the 
UK or Ireland with HIV infection or born to HIV-infected mothers are reported to the National 
Study of HIV in Pregnancy and Childhood (NSHPC); follow-up data on HIV-infected children 
are collected through CHIPS annually.  Children with no reported clinic visit for ≥24 months 
were considered lost to follow up, to allow for the delays in reporting. Both studies are 
approved by NHS Research Ethics Committees.  
 
The inclusion criteria for these analyses were: antiretroviral naïve (except neonatal 
prophylaxis for prevention of mother-to-child transmission (pMTCT)), age under 18 years at 
initiation of ART with at least three drugs (excluding unboosted PI or triple NRTI-based 
regimens not containing abacavir) started since 1996; and ≥1 viral load measurement within 
12 months of initiating ART. Patients were excluded if they: (1) initiated ART with a NRTI 
backbone combination of stavudine with didanosine or stavudine with zidovudine as 
guidelines recommend against combined use of these drugs7; (2) had participated in a 
clinical trial of treatment interruption and/or switching strategies (PENTA-11 or PENPACT1); 
(3) were on a treatment interruption at the time of VL rebound; (4)  switched while 
virologically suppressed (because the outcomes of interest all occur after VL rebound); (5) 
aged >18 years at VL rebound. 
 
We first included all children who achieved virological suppression <400c/ml after initiating 
first-line ART. Following suppression, confirmed VL rebound was defined as two consecutive 
VL measurements ≥400c/ml within six months of each other. Viral load measurements were 
routinely taken at three to six monthly intervals in most clinics and the VL ≥400 c/ml 
threshold was considered the most relevant to clinical care in the UK/Ireland. Data on 
patients were matched with the UK HIV Drug Resistance Database14 data from 1996-2012 
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using an algorithm matching key variables available in both datasets i.e. date of birth, 
soundex code, gender, initials, clinic etc.  
 
Following confirmed VL rebound, switch to second-line ART was defined as:  changing ≥3 
drugs simultaneously irrespective of reason; or changing ≥2 drugs for documented treatment 
failure (virological, immunological, clinical with or without resistance test); or changing 1 drug 
cross-class for documented treatment failure; or adding a drug from a new class to the 
regimen.  
 
Following VL rebound the outcomes of interest were: switch to second-line therapy; 
confirmed resuppression <400 c/ml (two consecutive samples) without switch; and neither 
switched nor resuppressed. Children were at risk from the date of first VL rebound to the 
earliest date of switch to second-line ART, confirmed resuppression without switch, death, or 
most recent clinic visit.  
 
Statistical methods 
 
To avoid overestimation of the cumulative incidence of switch, which is a potential problem 
when competing events are not independent of one another15, 16, we used competing risk 
analysis. Using the model proposed by Fine and Gray15, we calculated the cumulative 
incidence of the three outcomes: switch to second-line therapy, confirmed resuppression 
without switch, and neither switching nor resuppressing following VL rebound. In each model 
the competing risks were the two alternative outcomes and death. Potential risk factors for 
earlier switching were gender, first-line regimen, age and CD4% at ART initiation and age, 
CD4%, VL, duration on ART, and calendar year at VL rebound.  The initial regimen was 
categorised as boosted PI+NRTI, EFV+2NRTI, NVP+2NRTI, NNRTI+3NRTI and 3NRTI. A 
NNRTI+3NRTI regimen, also referred to as “baby cocktail” is prescribed in some UK clinics 
for infants <12 months17. Calendar year of rebound was categorised to broadly reflect 
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availability of new antiretroviral drugs as 1996-2003, 2004-2007 and 2008 onwards, with the 
latter period seeing the introduction of newer PIs (e.g. darunavir and atazanavir) used for 
first and second line regimens. A priori factors age and calendar year at VL rebound were 
included in all models. Models were built using backwards elimination (exit probability 
p>0·1), sub-hazard ratios were reported from the final model (adjusted sub-hazard ratios). 
Sensitivity analyses were carried out with higher thresholds for VL rebound, defined as 
confirmed VL ≥1,000c/ml and ≥5,000c/ml after previous suppression.   
 
Analyses are based on data reported to CHIPS to November 2013 and were performed 
using STATA version 13 (StataCorp, College Station, Texas). 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
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RESULTS 
 
Of 1,843 patients ever reported to CHIPS, 900 suppressed to VL <400c/ml within a year of 
starting ART (Figure 1). The median [IQR] age and CD4% at ART initiation were 7·9 years 
[3·1-11·9] and 15% [9-20] and median duration of follow up was 7·8 years [5·0-10·8] after 
first presentation. Of all eligible patients, 416 (46%) were male, two-thirds (70%) initiated 
first-line ART since 2003 and three-quarters (76%) initiated on NNRTI-based regimens 
(Table 1).  
 
Of the 900 patients who achieved VL suppression <400c/ml within 12 months of starting 
ART, 170 (18%) subsequently experienced VL rebound at median [IQR] 20·6 months [9·7-
40·5] after ART initiation (Table 1). The median age, viral load, CD4 count, and CD4% at VL 
rebound were 10·6 years [5·6-13·4], 3·6 log10 c/ml [3·1-4·2], 550 cells/µl [310-930], and 24% 
[17-32], respectively, and three-quarters of children initiated on a NNRTI-based regimen. 
Fifty one (30%) had already experienced some ART modifications not meeting the definition 
of switch prior to VL rebound. There were no deaths, three patients (2%) were lost to follow 
up and three experienced new/recurring CDC B or C events (two switched and one 
resuppressed without switch). 
 
Figure 2 shows the cumulative incidence of switch, resuppression without switch, and 
neither resuppressing nor switching following VL rebound. By 12 months following VL 
rebound, an estimated 38% of patients (95% confidence interval [CI] 30-45%) switched to 
second-line therapy, increasing to 48% (95% CI 40-55%) by 24 months. By 12 and 24 
months after VL rebound, an estimated 27% (95% CI 21-34%) and 31% (95% CI 24-38%) of 
patients resuppressed without switch, whilst the remaining 35% (95% CI 28-42%) and 22% 
(95% CI 16-29%) of patients neither resuppressed nor switched.  
 
Time to switch 
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In multivariate analyses, faster time to switch was independently associated with lower 
CD4% [adjusted sub-hazard ratio (aSHR): 0·89 per 5% increase (95% CI 0·78-1·01), 
p=0·07] and higher VL [aSHR: 1·88 per log10 c/ml increase (95% CI 1·39-2·55), p<0·0001] at 
time of VL rebound (Table 2). There was evidence of patients initiated on PI-based regimens 
being slower to switch [aSHR: 0·13 (95% CI 0·05-0·38)] and a suggestion of faster switch in 
children on 4-drug NNRTI-based regimens [aSHR: 1·78 (95% CI 0·81-3·92)] when 
compared to 3-drug efavirenz-based regimens (global p=0·001). There was also evidence to 
suggest that patients experiencing VL rebound in later calendar years were faster to switch 
compared with patients who failed in earlier calendar years (p=0·02).  
 
Sensitivity analysis of increasing the threshold of VL rebound 
 
In sensitivity analyses, increasing the threshold of VL rebound to 1,000c/ml and 5,000c/ml 
resulted in fewer patients meeting the definition of VL rebound (139 and 84 respectively), of 
whom a higher proportion switched to second-line and a lower proportion resuppressed 
without switch. By 12 months following VL rebound at 1,000c/ml and 5,000c/ml, an 
estimated 43% (95% CI 34-51%) and 52% (95% CI 41-62%) switched to second-line, while 
24% (95% CI 17-31%) and 15% (95% CI 8-23%) resuppressed without switch, respectively. 
At the higher VL rebound threshold of 1,000c/ml, 13 (54%) and 24 (22%) patients who 
initiated on PI-based and NNRTI-based regimens, re-suppressed without switch; at the 
increased VL rebound threshold of 5,000c/ml, 5 (42%) and 11 (16%) re-suppressed without 
switch respectively 
 
Patients who switched to second-line therapy 
 
Eighty-nine (52%) patients switched to second-line therapy at median 4·9 months [1·7-13·4] 
after VL rebound. Of patients who initiated on PI-based and NNRTI-based regimens, 5 
12 
(16%) and 76 (59%) switched to second-line therapy, respectively. Eighty two (92%) patients 
switched to receive a PI-based second line regimen, of whom 62 (76%) switched to 
lopinavir, 13 (16%) atazanavir, 6 (7%) darunavir and 1 (1%) fosamprenavir At 12 and 24 
months after switch to second-line ART, an estimated 85% (95% CI 75-91) and 73% (95% 
CI 62-82) of patients remained continuously suppressed <400c/ml, respectively.  
 
Patients who experienced confirmed resuppression 
 
Fifty-three (31%) patients resuppressed <400c/ml without switching to second-line therapy, 
at median 7·4 months [IQR 3·4-10·1] after VL rebound. Of these, nine (17%) made ART 
changes which did not meet the definition of switch and 44 (83%) made no ART changes; 
although 10/44 (23%) had a change in dose in line with growth. Of patients who initiated on 
PI-based and NNRTI-based regimens, 19 (61%) and 31 (24%) resuppressed without 
switching, respectively. Among the 44 patients who resuppressed with no ART changes, 17 
(39%) remained suppressed through to their most recent follow up visit (median 28·5 months 
[6·8-44·5] after VL rebound) and 27 (61%) had a further episode of virological failure (viral 
load ≥400c/ml) at median 12·6 months [5·3-25·1] after initial resuppression, of which 9/27 
(33%) subsequently switched to second-line therapy at median 20·8 months [8·8-45·1] after 
initial resuppression.  
 
Patients who remained non-suppressed and did not switch  
 
Twenty eight (16%) patients (seven on PI-, 20 on NNRTI- and one on NRTI-based regimens) 
had neither switched nor resuppressed at most recent clinic visit, median 26·8 months [5·5-
51·9] after VL rebound. Median follow up of these patients was 2·2 years [0·5-4·3] and 8 
patients were followed up for less than 6 months. Of the 28, three (11%) patients made no 
changes to their regimen and three (11%) increased their dose of all drugs in line with 
growth. Thirteen (46%) were off-ART at the end of follow-up and the remaining nine (32%) 
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made other ART changes: eight within-class changes (for simplification and toxicity); and 
one patient had repeated treatment interruptions due to poor compliance.  
 
Resistance testing 
 
Resistance tests performed up to six months prior to the confirmatory (second) VL rebound 
measurement and censor date were available for 102/170 (60%) children: 68/89 (76%) of 
those who switched; 17/53 (32%) who resuppressed, and 17/28 (61%) who neither 
resuppressed nor switched. Overall, major PI, NNRTI, and NRTI mutations were found in 
zero (0%), 70 (69%), and 61 (60%) patients, respectively, who started a regimen containing 
that drug class and had a resistance test during follow-up. The most common mutations 
present were M184V (found in 49% (48/102) of patients and associated with resistance to 
the NRTIs lamivudine, emtricitabine and abacavir), K103N (23%; 23/102), Y181C (20%; 
20/102), V106M (15%; 15/102) (all associated with resistance to NNRTIs), and thymidine 
analogue mutations (13%; 13/102). Of 68 children who switched following a resistance test, 
61 (90%) had mutations detected. Eighteen patients did not switch therapy despite having 
resistance to drugs in their ART regimen. Of these, 5 (28%) went on to resuppress <400c/ml 
(whilst taking the following drugs: three nevirapine, one efavirenz, one lopinavir) and 13 
(72%) neither switched nor resuppressed (seven nevirapine, four efavirenz, two lopinavir). 
Of patients who resuppressed, 12 (71%) had no resistance mutations detected; however, of 
patients who neither switched nor resuppressed only three (18%) had no resistance 
mutations. Table 3 shows the resistance mutation summary by regimen and outcome among 
children initiated on PI or NNRTI based regimens. Among patients who resuppressed 
without switch, no children on PIs had resistance to that drug class whereas 4/10 (40%) of 
children on NNRTIs had resistance mutations associated with that drug class. 
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DISCUSSION  
 
In this national cohort of HIV-infected children in the UK/Ireland, we found that 19% 
(170/900) of children experienced virological failure, of whom half switch to second-line ART 
and one third resuppressed without switch. The proportion who resuppressed without switch 
was higher than expected although similar findings have been reported in adult studies18-20. 
Among those with a resistance test available, 71% (12/17) of patients who resuppressed 
without switch had no detectable resistance mutations compared with 10% (7/68) of patients 
who switched. This indicates both that patients who resuppressed were less likely to have 
resistance mutations, and that resistance testing guided the decision to switch patients to 
second line therapy. Whilst treatment non-adherence is not routinely reported to CHIPS, as 
well as being difficult to measure quantitatively, it is likely that this was identified following VL 
rebound and addressed with the child and their carers. Interestingly, almost a third of 
children who experienced VL rebound made some ART drug changes, not meeting the 
switch criteria, prior to rebound; this indicates that issues surrounding adherence or drug 
intolerance may have already arisen prior to virologic failure. A quarter of children who 
initiated on a NNRTI-based ART regimen resuppressed following VL rebound; an 
unexpected outcome given the low resistance barrier associated with this drug class. The 
proportion resuppressing without switch was markedly higher at 61% (19/31) among those 
on PI-based first-line regimen, reflective of its high resistance barrier. Time to switch to 
second-line therapy was also significantly later in children on PI-based regimens. Switch 
occurred more rapidly in children with higher viral load, lower CD4% and later calendar year 
at VL rebound. This observation is similar to that in the IeDEA cohort in Southern Africa 
where children with more progressive disease (based on higher viral load, CD4% <25 at 
switch, CD4% decline >1%/month) were more likely to switch, while those taking a PI-based 
regimen were less likely to switch21, which also reflects WHO recommendations to not switch 
young children <3-years with VL rebound on PI-based regimens5. Reluctance to switch a 
child failing PI-based therapy without thorough assessment of adherence is reasonable 
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considering that viral escape is more likely due to poor adherence than resistance in this 
setting22. This is supported by the findings of the PENPACT-1 study that showed no PI-
resistance emerging despite delayed switching11; in our study resistance to PIs was also 
rare. 
 
Previous studies of children, primarily on NNRTI-based regimens, have shown similar rates 
of virological failure at 12 months, although some of these studies used different definitions 
of failure (single elevated viral load measurements)21, 23, 24. Among patients who switched to 
second-line therapy in our study, we found a median [IQR] time from VL rebound to switch of 
4·9 months [1·7-13·4] which is comparable or slightly shorter than studies in resource limited 
settings21, 25. When changing the VL rebound threshold to two consecutive viral load 
measurements above 1,000c/ml and 5,000c/ml, not surprisingly we found a higher estimated 
proportion of patients switching to second line therapy while the probability of resuppression 
without switch decreased with higher VL thresholds. Presumably this is associated with 
anxiety felt by clinicians about higher viral loads and an increased risk of developing 
resistance mutations. Among patients who switched to second-line ART, an estimated 85% 
(95% CI [75-91]) remained continuously suppressed <400c/ml at 12 months and 73% (95% 
CI [62-82]) at 24 months after switch.  These rates of suppression are comparable to recent 
reports from Thailand and Africa, where all patients initiated on a PI-based second line 
regimen26-28. Another study of paediatric response to second-line ART in South Africa 
showed significantly poorer VL suppression in children receiving NNRTI-based as opposed 
to PI-based second-line therapy29. Six months after regimen change, VL suppression was 
80% in the PI-based vs 25% in the NNRTI-based second-line group, although the sample 
was relatively small (n=74). The long term outcomes on second line therapy by regimen 
were not assessed in our study and warrants further investigation.   
 
There are some limitations to this study. First, CHIPS is a cohort study so there may be 
unmeasured underlying determinants influencing results. Second, we did not have 
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adherence data within the cohort so were unable to determine if adherence interventions 
accounted for resuppression in those who did not change ART. Third, our results in terms of 
rate of switch or resuppression are only applicable to settings with routine viral load 
monitoring and access to resistance testing, and to patients experiencing VL rebound 
following their initial first-line suppression. Fourth, there may be some resistance tests that 
we were unable to match to CHIPS patients; therefore the level of resistance may be under-
estimated. There may also be some selection bias on the part of clinicians in their decision 
of which patients upon, and when, to conduct resistance tests; this may be influenced by 
factors such as latest viral load, current ART regimen and perceived adherence. Finally, 
some patients may have switched but we were unable to identify this using the data. For 
example, patients who changed one or two ART drugs across class without documented 
reason for change were not considered to have switched (there were two cases like this). 
Similarly, patients who switched prior to confirmed VL rebound were excluded; it is possible 
that patients may have switched to second-line following a very high single VL result, and 
therefore the rate of switch may be underestimated. 
 
In conclusion, in our cohort half (89/170) of patients with VL rebound switched to second-line 
therapy and a third (53/170) resuppressed without switching ART. Of the remaining patients 
(28/170; 16%), half remained on a failing regimen and half interrupted therapy until the end 
of follow up. Reassuringly, switching to second-line therapy was faster in children on NNRTI-
based regimens with lower barriers to resistance, as well as those more at clinical risk with 
lower CD4% and higher viral load. Switching to second-line therapy was also faster in later 
calendar years, as more classes of second-line drugs, as well as child friendly formulations 
became available. Switching was delayed in patients taking boosted PI-based regimens; 
indeed clinicians are more likely to use such regimens in children who are likelier to have 
adherence issues and greater risk of viral rebound. PI-based regimens are known to have a 
more forgiving nature and the majority (19/31; 61%) of patients who initiated on PI-based 
ART regimens resuppressed without switch. More notably, a quarter of children who initiated 
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on NNRTI-based ART regimens resuppressed after viral rebound. The possibility of 
resuppression should be considered prior to switching, ideally informed by resistance test 
results and a review of adherence and dosing status, to ensure an optimal second line 
therapy can be found. 
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Figure 1. Flowchart showing eligibility of CHIPS patients for this analysis 
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Table 1. Characteristics of patients who: suppressed within 12 months of initiating first-line ART; 
experienced viral load rebound after suppressing within 12 months of initiating first-line ART 
  
Suppressed 
within 12 months 
of initiating first-
line ART 
Experienced viral 
load rebound after 
suppressing within 
12 months of 
initiating first-line 
ART 
  
   
Total number of patients 900  170  
     
Male 416 (46) 84 (49) 
Age at ART initiation, median in years 7·9 [3·1-11·9] 7·5 [2·6-11·2] 
     < 3 years 222 (25) 44 (26) 
CD4% at ART initiation , median 15 [9-20] 12 [6-17] 
Calendar year at ART initiation     
     1996-2003 270 (30) 86 (51) 
     2004-2007 328 (36) 53 (31) 
     2008- 302 (34) 31 (18) 
Regimen at ART initiation     
     Boosted PI+NRTI 171 (19) 31 (18) 
     EFV+2NRTI 373 (41) 53 (31) 
     NVP+2NRTI 199 (22) 51 (30) 
     NNRTI+3NRTI 113 (13) 23 (14) 
     3NRTI 44 (5) 12 (7) 
     
Age at VL rebound, median in years   10·6 [5·6-13·4] 
     0-2   23 (14) 
     3-6   34 (20) 
     7-10   32 (19) 
     11-13   46 (27) 
     14+   35 (21) 
CD4% at VL rebound   24 [17-32] 
CD4 cell count at VL rebound, cells/µl    550 [310-930] 
Viral load at VL rebound, log10 copies/ml   3·6 [3·1-4·2]  
Time on ART until VL rebound, months    20·6 [9·7-40·5] 
Calendar year at VL rebound     
     1996-2003   38 (22) 
     2004-2007   58 (34) 
     2008-   74 (44) 
Changes made to initial ART regimen prior to VL rebound     
     None   119 (70) 
     Any   51 (30) 
          Cross class   10 (6) 
          Within class   8 (5) 
          NRTI backbone only   30 (18) 
          Other     3 (2) 
ART, Antiretroviral therapy; EFV, Efavirenz; IQR, Interquartile range; NNRTI, Nonnucleoside reverse 
transcriptase inhibitor; NRTI, Nucleoside reverse transcriptase inhibitor; NVP, Nevirapine; PI, Protease 
inhibitor; VL, Viral load. 
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Figure 2. Cumulative incidence of switch, confirmed resuppression without switch and neither 
resuppression nor switch following VL rebound, using competing risk model 
 
 
  Switch Re-suppression without switch 
Neither re-suppression nor switch 
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Table 2. Factors associated with time to switch following viral load rebound using competing risk model 
    
Univariable   Multivariable 
 n SHR 95% CI P  SHR 95% CI P 
    
              
Gender (female v male) 170 1·02 0·67 - 1·54 0·93     
Age at ART initiation (per 5 years higher) 170 1·05 0·85 - 1·28 0·67     
CD4% at ART initiation (per 5% higher) 145 0·85 0·75 - 0·97 0·02     
Age at VL rebound (per 5 years higher) 170 1·09 0·88 - 1·34 0·44  1·26 0·96 - 1·65 0·10 
CD4% at VL rebound (per 5% higher) 160 0·90 0·80 - 1·00 0·04  0·89 0·78 - 1·01 0·07 
Viral load at VL rebound (per log10 copies/ml higher) 170 1·72 1·29 - 2·27 0·0002  1·88 1·39 - 2·55 <0·0001 
Time on ART until VL rebound (per 6 months higher) 170 1·02 0·96 - 1·09 0·44     
Regimen at ART initiation 170   0·01    0·001 
     EFV+2NRTI  1    1   
     NVP+2NRTI  0·88 0·54 - 1·44   1·21 0·69 - 2·13  
     Boosted PI+NRTI  0·18 0·07 - 0·48   0·13 0·05 - 0·38  
     NNRTI+3NRTI  0·90 0·46 - 1·74   1·78 0·81 - 3·92  
     ABC+2NRTI  0·76 0·40 - 1·43   1·45 0·73 - 2·91  
Calendar year at VL rebound 170   0·97    0·02 
     1996 - 2003  1    1   
     2004 - 2007  1·06 0·65 - 1·74   1·28 0·71 - 2·30  
     2008 - 2011   1·04 0·64 - 1·69     2·38 1·23 - 4·60   
ABC, Abacavir; ART, Antiretroviral therapy; CI, Confidence interval; EFV, Efavirenz;  NNRTI, Nonnucleoside reverse transcriptase 
inhibitor; NRTI, Nucleoside reverse transcriptase inhibitor; NVP, Nevirapine; PI, Protease inhibitor; SHR, Sub hazard ratio;  
VL, Viral load.  
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Table 3. Patient characteristics by initial ART regimen (PI or NNRTI) and outcome (switched or resuppressed) 
  
Initiated on PI-based regimen Initiated on NNRTI-based 
regimen 
  
Switched to      
second-line 
Resuppressed 
without switch 
Switched to 
second-line 
Resuppressed 
without switch 
     N (%) or median [IQR]     
         
n 5 (100) 19 (100) 76 (100) 31 (100) 
         
Male 3 (60) 10 (53) 36 (47) 15 (48) 
         
Age at VL rebound, in years         
     Median 12·6 [11·3,12·7] 13 [9·7,14·9] 10·7 [5·6,13·0] 5·3 [2·6,11·5] 
     <3 0 (0) 2 (11) 9 (12) 9 (29) 
     3-6 1 (20) 0 (0) 14 (18) 11 (36) 
     7-10 0 (0) 4 (21) 16 (21) 3 (10) 
     11-13 3 (60) 7 (37) 28 (37) 3 (10) 
     14+ 1 (20) 6 (32) 9 (12) 5 (16) 
         
VL at VL rebound (log10 copies/ml) 4 [3·9,5·1] 3·4 [2·9,3·7] 4 [3·5,4·4] 3·4 [3·0,4·0] 
         
CD4 count at VL rebound (cells/µl) 422 [122,449] 420 [245,605] 550 [340,910] 922 [378,1246] 
         
CD4% at VL rebound 7 [6,22] 22·5 [16,31] 24 [17,33] 27 [18,35] 
         
Time from VL rebound to outcome, months 2·3 [1·7,19·1] 7·4 [3·0,9·9] 4·6 [1·4,12·2] 6·4 [3·2,10·1] 
         
Calendar year at VL rebound         
     1996-2003 1 (20) 0 (0) 14 (18) 9 (29) 
     2004-2007 1 (20) 4 (21) 30 (40) 13 (42) 
     2008- 3 (60) 15 (79) 32 (42) 9 (29) 
         
Major resistance mutation(s) present (n=82)         
Number of patients with a resistance test 4  7  61  10  
     PI/NNRTI 0 (0) 0 (0) 55 (90) 4 (40) 
     NRTI 2 (50) 1 (14) 43 (70) 2 (20) 
ART, Antiretroviral therapy; EFV, Efavirenz; IQR, Interquartile range; NNRTI, Nonnucleoside reverse transcriptase 
inhibitor; NRTI, Nucleoside reverse transcriptase inhibitor; NVP, Nevirapine; PI, Protease inhibitor; VL, Viral load. 
   
 
